Palladio Biosciences, Inc. Named “Best in Show” at Mid-Atlantic Bio Angels 1st Pitch Life Science Competition
Mid-Atlantic Bio Angels (MABA), an angel investor group focused on early-stage life science companies, announced that Palladio Biosciences, Inc. was voted as “Best in Show” at MABA's 1st Pitch Life Science competition, which took place at the Cira Center in Philadelphia, PA on March 17, 2016. Pryor Cashman Partner Stephen M. Goodman is a co-founder of MABA.
“Palladio effectively conveyed the scientific evidence supporting their therapeutic hypothesis, as well as the market opportunity. The company has laid an excellent foundation for future growth and investment,” said Goodman.
Palladio Biosciences, Inc. is a specialty pharma company dedicated to the treatment of orphan diseases of the kidney, with specific emphasis on autosomal dominant and autosomal recessive Polycystic Kidney Disease. Given the complexity of these diseases, the company aims to deploy a multi-pronged approach to provide much needed relief to patients suffering from these devastating diseases. In particular, the company targets initiation of registration Phase 3 studies for its lead drug for autosomal dominant Polycystic Kidney Disease in 9‐12 months.
